Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus
VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.
Fidelity MSCI Health Care Index ETF and VanEck Pharmaceutical ETF present contrasting investment strategies within the healthcare sector. The former delivers extensive, cost-effective exposure across the entire healthcare industry, encompassing equipment, services, and pharmaceuticals. Conversely, the latter concentrates on a narrow focus, specifically targeting global pharmaceutical giants.
Investors must weigh the trade-off between industry breadth and specialized focus when deciding between these two funds. Both play the role of defensive anchors in an equity portfolio, but they differ markedly in construction. The Fidelity fund encompasses a wide array of medical-related industries, while the VanEck fund zeroes in on the world's leading drug manufacturers.
Understanding which approach aligns better with one's portfolio requires a closer look at key metrics. The beta of an ETF measures its price volatility relative to the S&P 500, calculated from monthly returns spanning the available fund history (up to five years). The 1-year return represents the total return over the trailing 12 months. Lastly, the dividend yield is the trailing-12-month distribution yield as of the close of trading on August 20, 2026.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
